- $34.23m
- -$184.22m
- 27
- 54
- 75
- 50
Annual income statement for LianBio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 24.3 | 135 | 196 | 125 |
| Operating Profit | -24.3 | -135 | -196 | -125 |
| Total Net Non Operating Interest Income / Expense | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -24.3 | -140 | -196 | -111 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -24.3 | -140 | -196 | -110 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -24.3 | -140 | -196 | -110 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -24.3 | -140 | -196 | -110 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.231 | -1.33 | -1.86 | -1.02 |